Meeting
2018 Gastrointestinal Cancers Symposium
The impact of Tfh cell/ B cell pathway-related genetic variants in metastatic colorectal cancer patients with bevacizumab-based chemotherapy.
Authors
Ryuma Tokunaga
USC Keck School of Medicine, Los Angeles, CA
Ryuma Tokunaga , Shu Cao , Wu Zhang , Alberto Puccini , Martin D Berger , Madiha Naseem , FRANCESCA BATTAGLIN , Shivani Soni , Michelle McSkane , Sebastian Stintzing , Fotios Loupakis , Volker Heinemann , Alfredo Falcone , Joshua Millstein , Heinz Josef Lenz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 651)
DOI
10.1200/JCO.2018.36.4_suppl.651
Abstract #
651
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2019 Gastrointestinal Cancers Symposium
Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.
First Author: Ryuma Tokunaga
Poster
2023 ASCO Annual Meeting
Single nucleotide polymorphisms (SNPs) in MHC class I and II genes to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3, MAVERICC, and TRIBE trials.
First Author: Pooja Mittal
Poster
2021 ASCO Annual Meeting
Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.
First Author: Jingyuan Wang
Poster
2021 ASCO Annual Meeting
Germline polymorphisms in genes maintaining replication fork to predict the efficacy of oxaliplatin and irinotecan in metastatic colorectal cancer (mCRC) patients enrolled in MAVERICC trial.
First Author: Hiroyuki Arai